ArticleDrug design, development and therapy2025
Plasma Concentrations of Prophylactic Posaconazole and Risk Factors for Subtherapeutic Exposure in Taiwanese Patients with Hematologic Malignancies.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk Factors for Subtherapeutic Exposure and Hepatotoxicity Threshold of Posaconazole: A Real-World Study in Chinese Patients with Invasive Pulmonary Fungal Infection.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Posaconazole is widely used for antifungal prophylaxis in patients with hematologic malignancies. However, interindividual pharmacokinetic variability may lead to subtherapeutic exposure and treatment failure. Real-world data on the pharmacokinetics of posaconazole tablets and infusion in East Asian populations remain limited. This study aims to evaluate the plasma concentration of posaconazole and risk factors for subtherapeutic exposure in Taiwanese patients. Methods: This nested case-control study was conducted using data from the National Taiwan University Hospital database. The study cohort comprised adult patients with hematologic malignancies receiving delayed-release tablets or intravenous formulations of posaconazole and undergoing therapeutic drug monitoring. Factors associated with subtherapeutic posaconazole exposure (<0.7 μg/mL) were identified through multivariate logistic regression. Supratherapeutic concentration was defined as a level >1.83 μg/mL. Results: Of a total of 221 patients, 24.9% and 24.0% exhibited subtherapeutic and supratherapeutic posaconazole concentrations, respectively. Multivariate logistic regression indicated that male sex (odds ratio [OR] = 2.31), diarrhea (OR = 2.18), and concurrent use of proton pump inhibitors (OR = 2.00) or prokinetic agents (OR = 2.17) were independently associated with subtherapeutic exposure to posaconazole. Conclusion: Subtherapeutic and supratherapeutic exposures to posaconazole remain a concern despite standard dosing. Therapeutic drug monitoring and personalized risk assessment are essential for optimizing antifungal prophylaxis in patients with hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.